SCHEMBL897276

SCHEMBL897276

COc1ccc2c(c1)C(C)(C)c1[nH]c3ccc([N+](=O)[O-])cc3c1C2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 1/20 0.57
CTSL P07711 1/20 0.57
CCNB2 O95067 6/20 0.57
CDK1 P06493 6/20 0.57
CCNB1 P14635 6/20 0.57
GSK3B P49841 6/20 0.57
CDK5 Q00535 6/20 0.57
CDK5R1 Q15078 6/20 0.57
CCNB3 Q8WWL7 6/20 0.57
CFTR P13569 1/20 0.46
CCNE1 P24864 2/20 0.45
CDK2 P24941 2/20 0.45
MAPT P10636 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHRM4 P08173 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17066405 0.82 CA1 (0.44) CCNB2CDK1CCNB1GSK3BCDK5
SCHEMBL20004295 0.81 CA1 (0.46) CCNB2CDK1CCNB1GSK3BCDK5
SCHEMBL20366624 0.81 CA1 (0.41) CCNB2CDK1CCNB1GSK3BCDK5
SCHEMBL898301 0.79 ALK (0.59) CTSVCTSLCCNB2CDK1CCNB1
SCHEMBL898273 0.78 CA1 (0.41) CFTRMAPTMEN1KMT2ALMNA
SCHEMBL1181214 0.76 CTSV (0.86) CTSVCTSLCCNB2CDK1CCNB1
SCHEMBL896972 0.74 CDK4 (0.46) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL897959 0.74 CA1 (0.43) CFTRMAPTMEN1KMT2ALMNA
SCHEMBL1755953 0.74 CA1 (0.39) CFTRMAPTKMT2AALDH1A1CA1
SCHEMBL897520 0.72 ALK (0.52) CCNB2CDK1CCNB1GSK3BCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 US disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 EP disclosed
EP-3345903-A1 TETRACYCLIC COMPOUNDS Chugai Seiyaku Kabushiki Kaisha (JP) 2018-07-11 EP disclosed
EP-2975024-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-03-28 EP disclosed
US-20160340308-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-24 US disclosed
US-9440922-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-13 US disclosed
EP-2441753-B1 TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-03-30 EP disclosed
EP-2441753-B1 TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-03-30 EP disclosed
EP-2975024-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-20 EP disclosed
EP-2975024-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-20 EP disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 US disclosed
WO-2010143664-A1 TETRACYCLIC COMPOUND 中外製薬株式会社 (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CTSV 4269/4885CTSL 2555/4885CCNB2 1243/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CTSV 4269/4885CTSL 2555/4885CCNB2 1243/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CTSV 4269/4885CTSL 2555/4885CCNB2 1243/4885
US-20160340308-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CTSV 4269/4885CTSL 2555/4885CCNB2 1243/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CTSV 4269/4885CTSL 2555/4885CCNB2 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.